April Hill
Optometrist · Montgomery, ALNPI 1962796714
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.5% of the total across 238 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Lumenis BE Inc at 26.7% of the total. 2025 is the largest year on record at $3,119, 6.5 times the $481 reported in 2019. Among optometrist clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 238 payments — averaging $31.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lumenis BE Inc$2K
- Sun Pharmaceutical Industries Inc.$1K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$746
- Johnson & Johnson Vision Care, Inc.$585
- Bausch & Lomb Americas Inc.$521
- Alcon$505
- plus $2K from 11 others
What the payments were for
- Food & beverage$7,15297%
- Education$180%
- Gifts$190%
- Entertainment$2193%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lumenis BE Inc | 1 | $1,980 |
| Sun Pharmaceutical Industries Inc. | 63 | $1,483 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 32 | $746 |
| Johnson & Johnson Vision Care, Inc. | 28 | $585 |
| Bausch & Lomb Americas Inc. | 26 | $521 |
| Alcon | 28 | $505 |
| Optos, Inc. | 7 | $398 |
| Coopervision Inc. | 19 | $337 |
| Tarsus Pharmaceuticals, Inc. | 9 | $215 |
| Glaukos Corporation | 1 | $149 |
| AbbVie | 5 | $135 |
| Kala Pharmaceuticals, Inc. | 7 | $116 |
| Novartis | 7 | $108 |
| Topcon Healthcare, Inc. | 1 | $47 |
| Maculogix, Inc. | 2 | $40 |
| Oyster Point Pharma, Inc. | 1 | $23 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- M22$1,980
- PANORAMIC OPHTHALMOSCOPE$262
- OCT OPHTHALMOSCOPE$262
- CEQUA$239
- KXL System$149
- Photrexa$149
- NFC-700$131
How this compares
$7,408 in reported general payments places this provider in the 95th percentile of 749 optometrist providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 39 | $39,887 |
| Cyclosporine | 27 | $22,340 |
| XiidraLifitegrast | 12 | $19,460 |
| LumiganBimatoprost | 15 | $7,775 |
| CequaCyclosporine | 12 | $6,757 |
| Loteprednol Etabonate | 29 | $4,343 |
| VyzultaLatanoprostene Bunod | 17 | $4,190 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 28 | $4,184 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 25 | $3,474 |
| Latanoprost | 119 | $1,676 |
| ValacyclovirValacyclovir Hcl | 12 | $656 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 35 | $536 |
| Prednisolone Acetate | 13 | $368 |
| ErythromycinErythromycin Base | 23 | $212 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 12 | $150 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $135 | $47,66254 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $521 | $23,65029 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $1,483 | $6,75712 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $746 | $4,34329 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 749 optometrist providers in Alabama.
Other optometrist in Montgomery
- Ashley WareMontgomery$9K
- Michael MullMontgomery$7K
- Tyler McFadenMontgomery$6K
- Mark SchaefferHoover$470K
- Kelly NicholsBirmingham$231K
- Benjamin KachelmanFlorence$101K
- Neena JamesHuntsville$74K
- Tracey Schroeder SwartzHuntsville$69K
- Jack SchaefferHoover$60K
- Leo SemesBirmingham$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.